Harrow Health (NASDAQ:HROW) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Analysts have set a 1-year consensus price target of $11.38 for the company and are expecting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Harrow Health an industry rank of 150 out of 256 based on the ratings given to related companies.
Several brokerages have recently commented on HROW. ValuEngine raised shares of Harrow Health from a “hold” rating to a “buy” rating in a report on Monday, June 24th. Zacks Investment Research cut shares of Harrow Health from a “buy” rating to a “hold” rating in a research note on Wednesday, May 15th. Finally, TheStreet raised shares of Harrow Health from a “d-” rating to a “c” rating in a research note on Wednesday, May 1st.
Harrow Health (NASDAQ:HROW) last announced its earnings results on Thursday, May 9th. The company reported ($0.02) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.12 by ($0.14). Harrow Health had a return on equity of 100.84% and a net margin of 65.84%. The business had revenue of $12.29 million for the quarter, compared to the consensus estimate of $12.10 million. As a group, sell-side analysts forecast that Harrow Health will post -0.1 EPS for the current year.
In related news, Director Robert J. Kammer sold 10,000 shares of Harrow Health stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $4.57, for a total value of $45,700.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 30,000 shares of company stock worth $151,200 over the last three months. 12.43% of the stock is currently owned by insiders.
A number of large investors have recently made changes to their positions in HROW. FineMark National Bank & Trust bought a new position in Harrow Health in the first quarter valued at approximately $113,000. EAM Global Investors LLC bought a new stake in shares of Harrow Health during the first quarter worth $171,000. Institutional & Family Asset Management LLC bought a new stake in shares of Harrow Health during the first quarter worth $195,000. Alambic Investment Management L.P. bought a new stake in shares of Harrow Health during the first quarter worth $252,000. Finally, Birchview Capital LP bought a new stake in shares of Harrow Health during the first quarter worth $896,000. 32.14% of the stock is currently owned by institutional investors and hedge funds.
Harrow Health Company Profile
Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.
Featured Story: What are momentum indicators and what do they show?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.